Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects

1,091 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. (2012, background): “encouraging that long-term survival after treatment with curative intent at early stages of the disease may now reach 50% to 70% over 5 years [101].”
Management of hepatocellular carcinoma: An update (2011, neutral): “These lesions have been called ‘‘very early HCC’’ in the Barcelona Clinic Liver Cancer (BCLC) staging scheme.(194) The pathology of these ‘‘very early HCC’’ lesions has been defined in resected specimens, and therefore, the natural history of these lesions is unknown.”
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “The natural outcome of these cases is ill-defined because of the scarcity of data reported, but median survival is estimated to be around 36 months.(303) An improvement in survival is universal when applying the so-called treatment-”
Hepatocellular carcinoma: a review (2016, background): “Currently, there are several treatment options, both surgical and nonsurgical, that can have a positive impact on survival.(88) The best outcomes are achieved when patients”
Hepatocellular carcinoma: a global view (2010, background): “The best supportive care is recommended for patients with terminal (stage D) HCC”